Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common heart drug tame nosebleeds in rare disease?

NCT ID NCT04113187

Terminated Symptom relief Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether propranolol, a beta-blocker usually used for heart conditions, can reduce nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT), a genetic disorder that causes abnormal blood vessels. Fifteen adults with HHT took either propranolol or a placebo for three months. The main goal was to see if the drug shortened the total time of nosebleeds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
propranolol
What this could lead to
If it works, this could offer a new way to reduce nosebleeds in people with HHT, improving daily life.
What could go wrong
This is a very small, completed phase 3 trial with only 15 participants, so results may not apply to everyone. Propranolol can cause side effects like low blood pressure and fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Epistaxis hereditary hemorrhagic telangiectasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY HEMORRHAGIC TELANGIECTASIA OSLER WEBER RENDU DISEASE

Contacts and locations

Locations

  • CHU de Bordeaux - service de médecine interne

    Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.